Videos

“We call it ‘trimodality therapy,’ because it involves the 3 main disciplines: surgery, radiation oncology, and medical oncology,” says Kamran.

Dr Jason Hafron concludes his discussion of mCSPC by highlighting the need to work towards a cure for the disease, and two major clinical trials investigating triplet treatment regimens.

Jason Hafron, MD, revisits the patient profile and discusses factors that inform treatment decision-making in mCSPC.

An expert provides an overview of the types of androgen deprivation therapy (ADT) for mCSPC, other therapies that can be used in combination with ADT for treatment intensification and compares the safety and efficacy of the various regimens.

Jason Hafron, MD, presents the profile of a 66-year-old man with metastatic castration-sensitive prostate cancer (mCSPC).

Axonics F15, a recharge-free sacral neuromodulation implantable neurostimulator for the treatment of patients with bladder and bowel dysfunction, was approved by the FDA earlier this year.

I think we need to really carefully listen to and pay attention to our APPs’ needs,” says Amanda C. North, MD.

Dr Mark Emberton shares what developments are visible on the horizon and what they represent for the future of focal therapy and treatment of clinically localized prostate cancer.

An expert’s brief commentary on follow-up strategies in patients receiving focal therapy, including monitoring for disease relapse or recurrence.

An experienced clinician shares his personal experience with preventing and managing side effects related to focal therapy in patients with clinically localized prostate cancer.

A focused discussion on how the availability and use of focal therapy technology has changed treatment paradigms and affected patient outcomes.

An oncologic urologist from the United Kingdom (UK) discusses the diffusion of focal therapy options for clinically localized prostate cancer in the United States and UK.

Dr Mark Emberton reviews safety and efficacy data supporting the use of focal therapy in patients with prostate cancer.

An in-depth discussion of emerging focal therapy options for clinically localized prostate cancer.

Insights on the drawbacks of older treatment approaches for clinically localized prostate cancer and how strategically implementing focal therapies may address remaining unmet needs and clinical challenges.

Dr Emberton provides a historical perspective of treatment options for clinically localized prostate cancer and discussed how use of these options has evolved over time.

A prostate cancer specialist breaks down prostate cancer staging and grading and identifies several shortcomings of established risk stratification methods for patients with clinically localized disease.

Mark Emberton, BSc, MBBS, FRSC (Urol), MD, FMedSci describes his approach to diagnosing patients with prostate cancer, highlighting prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI) as critical to cancer detection.

Pramit Khetrapal, MD, discusses the abstract, “Results of the intracorporeal robotic vs open cystectomy multi-centre randomised trial,” which he presented at the 2022 AUA Annual Meeting.

“We saw that with each additional enrichment feature the odds of finding a germline mutation would double,” says Alexis Rompré-Brodeur, MD.

“Coordination between urology and radiation oncology, if urology is placing the device, is really critical,” says Jonathan E. Shoag, MD.

In the third interview of the series, Sam S. Chang, MD, MBA, from the Vanderbilt University Medical Center shares key insights into the role of mitomycin gel as a kidney-sparing approach to the treatment of low-grade upper tract urothelial carcinoma.

“With an increase in medical and surgical therapies in younger individuals, health care providers must discuss fertility preservation options prior to affirmation therapy,” says Niki Parikh, MD, MBA, MSBA.

“The open operation is obviously done using a single incision that is quite big,” says Khetrapal.

“I think there is still a burden on women more than on men to manage everything, all at once simultaneously. And that leads to burnout, because you're constantly feeling pulled in multiple directions,” says Amanda C. North, MD.

A review of the currently available genomic testing options for patients with clinically localized prostate cancer and the NCCN and AUA/ASTRO recommendations based on risk group.

Stephen J. Freedland, MD, details which patient populations he orders genomic testing for, and how the tests can address clinical challenges in prostate cancer treatment.

“UGN-102 may offer a patient-centered therapeutic approach, more patient centered than standard treatments like surgery,” says Angela M. Stover, PhD.

“Healthy Now is really committed to making access to care available to all men,” says Mohit Khera, MD, MBA, MPH.

“Each patient is different, and some patients are more challenging than others in terms of placement,” says Jonathan E. Shoag, MD.